Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

CHRS

Coherus Oncology Inc

Jun 06 • 04:00PM ET

0.8300

Dollar change +0.0243
Percentage change 3.02	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN GILD ABBV VRTX REGN BIIB INCY BMRN NBIX EXEL

| Held by: VTI IWM VXF VTWO IWN SCHA VHT IWO IWC PRFZ

Index	RUT	P/E	-	EPS (ttm)	-1.13	Insider Own	3.89%	Shs Outstand	115.91M	Perf Week	6.55%
Market Cap	96.22M	Forward P/E	-	EPS next Y	-0.82	Insider Trans	-2.17%	Shs Float	111.42M	Perf Month	-12.28%
Income	-130.94M	PEG	-	EPS next Q	-0.26	Inst Own	51.07%	Short Float	29.72%	Perf Quarter	-20.19%
Sales	197.50M	P/S	0.49	EPS this Y	-626.69%	Inst Trans	-5.56%	Short Ratio	18.31	Perf Half Y	-51.46%
Book/sh	-1.58	P/B	-	EPS next Y	37.57%	ROA	-21.46%	Short Interest	33.12M	Perf Year	-53.37%
Cash/sh	0.71	P/C	1.17	EPS next 5Y	-	ROE	-	52W Range	0.66 - 2.43	Perf YTD	-39.86%
Dividend Est.	-	P/FCF	192.44	EPS past 5Y	-27.36%	ROI	-114.62%	52W High	-65.84%	Beta	0.88
Dividend TTM	-	Quick Ratio	1.20	Sales past 5Y	-5.60%	Gross Margin	54.21%	52W Low	25.70%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	1.22	EPS Y/Y TTM	-62.19%	Oper. Margin	-54.64%	RSI (14)	48.26	Volatility	0.77% 5.64%
Employees	228	Debt/Eq	-	Sales Y/Y TTM	-34.58%	Profit Margin	-66.30%	Recom	2.00	Target Price	4.68
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	-159.59%	Payout	0.00%	Rel Volume	1.03	Prev Close	0.81
Sales Surprise	-86.10%	EPS Surprise	-37.86%	Sales Q/Q	-90.14%	Earnings	May 12 AMC	Avg Volume	1.81M	Price	0.83
SMA20	2.51%	SMA50	-6.81%	SMA200	-24.02%	Trades		Volume	1,867,296	Change	3.02%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-16-24	Downgrade	UBS	Buy → Neutral	$4 → $1.50
Nov-17-23	Initiated	Robert W. Baird	Outperform	$11
Nov-08-23	Downgrade	Maxim Group	Buy → Hold
Jul-24-23	Initiated	Citigroup	Buy	$12
May-01-23	Initiated	Truist	Buy	$24
Mar-28-23	Upgrade	UBS	Neutral → Buy	$11
Jun-14-22	Initiated	UBS	Neutral	$7
Mar-07-22	Downgrade	JP Morgan	Overweight → Neutral	$15
Jul-16-20	Initiated	BofA Securities	Neutral	$20
Apr-17-20	Initiated	SunTrust	Buy	$26
Aug-13-19	Initiated	Mizuho	Buy
Aug-02-19	Reiterated	Maxim Group	Buy	$25 → $27
Aug-02-19	Reiterated	H.C. Wainwright	Buy	$28 → $29
Jun-11-19	Initiated	Barclays	Overweight	$30
May-07-19	Initiated	H.C. Wainwright	Buy	$28
Aug-28-18	Initiated	H.C. Wainwright	Buy	$28
Mar-09-18	Reiterated	Maxim Group	Buy	$20 → $15
Aug-08-17	Reiterated	JP Morgan	Overweight	$32 → $25
Jun-13-17	Reiterated	Maxim Group	Buy	$44 → $40
May-05-17	Initiated	BMO Capital Markets	Outperform	$54

Show Previous Ratings

Jun-06-25 04:29PM	Coherus BioSciences, Inc. (CHRS): A Bull Case Theory (Insider Monkey)
May-30-25 08:00AM	Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics (GlobeNewswire)
May-27-25 08:30AM	Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI (toripalimab-tpzi) (GlobeNewswire)
May-13-25 02:22PM	Q1 2025 Coherus BioSciences Inc Earnings Call (Thomson Reuters StreetEvents) -19.11%
03:10AM	Coherus BioSciences Inc (CHRS) Q1 2025 Earnings Call Highlights: Strategic Growth and ... (GuruFocus.com)
05:30PM	Loading…
May-12-25 05:30PM	Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +5.30%
04:27PM	Coherus BioSciences: Q1 Earnings Snapshot (Associated Press Finance)
04:15PM	Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-09-25 09:45AM	What To Expect From Coherus BioSciences Inc (CHRS) Q1 2025 Earnings (GuruFocus.com)
May-05-25 04:01PM	Coherus to Report First Quarter 2025 Financial Results on May 12, 2025 (GlobeNewswire) -7.27% -8.83%
May-01-25 05:04PM	Coherus to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-28-25 10:10AM	Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025 (GlobeNewswire)
Apr-17-25 05:53AM	Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs (Seeking Alpha) +10.89%
Apr-15-25 09:44AM	Coherus divests Udenyca franchise to Intas for up to $558.4m (Pharmaceutical Technology) +8.76%
Apr-14-25 08:00AM	Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA Franchise (GlobeNewswire) +16.59%
08:00AM	Loading…
Apr-01-25 08:00AM	Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes (GlobeNewswire)
Mar-25-25 04:30PM	Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) -5.81%
Mar-21-25 07:10AM	Lazard Enhanced Opportunities Portfolio Q4 2024 Commentary (SeekingAlpha) +8.83%
Mar-14-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
Mar-12-25 03:23PM	Coherus BioSciences, Inc. (CHRS): A Bull Case Theory (Insider Monkey) -6.67%
Mar-11-25 01:46PM	Q4 2024 Coherus BioSciences Inc Earnings Call (Thomson Reuters StreetEvents)
03:02AM	Coherus BioSciences Inc (CHRS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Mar-10-25 04:32PM	Coherus BioSciences: Q4 Earnings Snapshot (Associated Press Finance)
04:12PM	Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-07-25 07:06AM	What To Expect From Coherus BioSciences Inc (CHRS) Q4 2024 Earnings (GuruFocus.com)
Mar-03-25 08:30AM	Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025 (GlobeNewswire) -9.46%
Feb-24-25 09:08AM	Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference (GlobeNewswire) +7.48%
Feb-12-25 08:39AM	Coherus BioSciences, Inc. (CHRS): A Bull Case Theory (Insider Monkey)
Jan-22-25 07:00AM	Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 (GlobeNewswire)
Jan-08-25 08:00AM	Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
08:30AM	Loading…
Dec-18-24 08:30AM	Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 (GlobeNewswire) -8.19%
Dec-03-24 07:00AM	Coherus Announces Agreement to Divest UDENYCA Franchise for up to $558 million to Intas Pharmaceuticals Ltd. (GlobeNewswire) +24.82%
06:06AM	Coherus, sharpening immuno-oncology focus, sells another biosimilar for over $500M (BioPharma Dive)
Nov-27-24 04:01PM	Coherus Management to Participate in the 2024 Citi Global Healthcare Conference (GlobeNewswire)
Nov-07-24 01:09PM	Q3 2024 Coherus BioSciences Inc Earnings Call (Thomson Reuters StreetEvents) +13.29%
02:26AM	Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
Nov-06-24 05:15PM	Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:11PM	Coherus BioSciences: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-05-24 08:08AM	Coherus BioSciences Inc (CHRS) Q3 2024: Everything You Need to Know Ahead of Earnings (GuruFocus.com) +9.10%
Oct-30-24 04:20PM	Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024 (GlobeNewswire)
Oct-09-24 06:01PM	Coherus BioSciences Inc (CHRS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Sep-28-24 07:24AM	Coherus BioSciences, Inc. (CHRS): Worst 52-Week Low Stock to Buy Now (Insider Monkey)
Sep-25-24 11:28AM	Short Interest Surges to 21.83% as Coherus BioSciences, Inc. (CHRS) Faces Revenue Challenges (Insider Monkey)
Aug-08-24 05:50PM	Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +10.85%
04:45PM	Coherus BioSciences: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-01-24 09:00AM	Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024 (GlobeNewswire) -7.14%
Jun-28-24 07:49AM	PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar (BioPharma Dive)
Jun-27-24 08:26AM	Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction (GlobeNewswire)
Jun-05-24 09:00AM	Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors (GlobeNewswire)
May-30-24 09:00AM	Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference (GlobeNewswire)
May-23-24 05:51PM	Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
09:00AM	Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA (GlobeNewswire)
May-13-24 09:23AM	Truist Securities Trims Price Target on Coherus BioSciences to $7 From $8, Maintains Buy Rating (MT Newswires) +10.00%
May-10-24 04:45PM	Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2024 Earnings Call Transcript (Insider Monkey) -10.38%
May-09-24 05:15PM	Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:12PM	Coherus BioSciences: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
07:30AM	Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan (GlobeNewswire)
May-08-24 09:00AM	Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer (GlobeNewswire)
May-01-24 04:30PM	Coherus to Report First Quarter 2024 Financial Results on May 9, 2024 (GlobeNewswire) +5.10% +5.34%
Apr-24-24 10:02AM	Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) -7.34%
Apr-08-24 08:30AM	Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting (GlobeNewswire)
Mar-16-24 03:35PM	Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-14-24 06:28PM	Why Coherus Biosciences Stock Tumbled on Thursday (Motley Fool) -5.65%
07:15AM	Q4 2023 Coherus BioSciences Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-13-24 05:32PM	Coherus BioSciences Inc (CHRS) Reports Growth in Net Revenue for Q4 and Full Year 2023 Despite ... (GuruFocus.com)
04:13PM	Coherus BioSciences: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update (GlobeNewswire)
Mar-05-24 04:01PM	Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024 (GlobeNewswire)
Mar-04-24 01:00AM	Coherus Completes Divestiture of Ophthalmology Franchise (GlobeNewswire) -5.81%
Feb-23-24 05:33PM	Coherus BioSciences Announces New Employment Inducement Grants (GlobeNewswire)
Feb-21-24 08:30AM	Coherus Announces U.S. Launch of UDENYCA ONBODY a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv (GlobeNewswire)
Feb-06-24 05:16PM	Why Coherus BioSciences Stock Jumped Today (Motley Fool) +14.85%
Feb-05-24 08:00AM	Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP (GlobeNewswire)
Jan-23-24 11:37AM	Why Coherus BioSciences Stock Is Sinking Today (Motley Fool) -6.98%
Jan-22-24 03:41PM	Why Coherus Biosciences Popped Today (Motley Fool) +5.74%
08:38AM	Why Is Coherus BioSciences (CHRS) Stock Up 17% Today? (InvestorPlace)
01:15AM	Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal (GlobeNewswire)
Jan-18-24 04:05PM	Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium (GlobeNewswire)
Jan-12-24 03:06AM	Here's Why Aristotle Small Cap Equity Strategy Sold Coherus BioSciences (CHRS) (Insider Monkey)
Jan-04-24 08:00AM	INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI (toripalimab-tpzi) (PR Newswire)
Jan-03-24 09:00AM	Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-02-24 08:29AM	Coherus Announces U.S. Launch of LOQTORZI (GlobeNewswire) -5.71%
Dec-28-23 03:45PM	Why Coherus BioSciences Stock Jumped Today (Motley Fool) +20.45%
11:07AM	Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca Onbody (Zacks)
Dec-27-23 05:07PM	These Stocks Moved the Most Today: Tesla, Apple, Coinbase, MicroStrategy, Iovance, NetEase, and More (Barrons.com) +23.39%
01:06PM	These Stocks Are Moving the Most Today: Tesla, Apple, Coinbase, MicroStrategy, Iovance, NetEase, and More (Barrons.com)
Dec-26-23 04:01PM	Coherus Announces FDA Approval of UDENYCA ONBODY , a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv (GlobeNewswire) +7.92%
Dec-24-23 09:45AM	2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street (Motley Fool)
Dec-22-23 05:00PM	Coherus BioSciences Announces New Employment Inducement Grants (GlobeNewswire) +7.92%
Dec-11-23 08:30AM	Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx (GlobeNewswire)
Dec-07-23 05:55PM	Coherus BioSciences Announces CFO Transition Plans (GlobeNewswire)
Dec-06-23 04:00AM	Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress (GlobeNewswire)
Nov-28-23 11:16AM	Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association (GlobeNewswire) +8.76%
Nov-10-23 03:15PM	Why Coherus BioSciences Was Plummeting This Week (Motley Fool)
Nov-07-23 03:37PM	Why Coherus Biosciences Stock Dropped Today (Motley Fool) -30.23%
10:46AM	Coherus BioSciences, Inc. (NASDAQ:CHRS) Q3 2023 Earnings Call Transcript (Insider Monkey)
10:19AM	Q3 2023 Coherus BioSciences Inc Earnings Call (Thomson Reuters StreetEvents)

Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and LOQTORZI. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wahlstrom Mats	Director	May 23 '25	Sale	0.74	99,988	73,881	0	May 28 05:12 PM

Dollar change +0.05
Percentage change 0.94	%

TLSI TriSalus Life Sciences Inc daily Stock Chart

Peers: CRSP NTLA FATE IMTX EDIT BLUE SGMO ADAP CELU SLDB

| Held by: VXF VTI

Index	-	P/E	-	EPS (ttm)	-1.12	Insider Own	58.16%	Shs Outstand	32.27M	Perf Week	7.80%
Market Cap	203.95M	Forward P/E	-	EPS next Y	-0.17	Insider Trans	0.40%	Shs Float	15.83M	Perf Month	3.65%
Income	-30.31M	PEG	-	EPS next Q	-0.21	Inst Own	8.11%	Short Float	0.69%	Perf Quarter	0.56%
Sales	32.14M	P/S	6.35	EPS this Y	37.75%	Inst Trans	4.40%	Short Ratio	2.19	Perf Half Y	28.33%
Book/sh	-1.06	P/B	-	EPS next Y	78.69%	ROA	-117.01%	Short Interest	0.11M	Perf Year	-26.77%
Cash/sh	0.34	P/C	15.69	EPS next 5Y	-	ROE	-	52W Range	3.50 - 7.19	Perf YTD	7.58%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-175.42%	ROI	-	52W High	-25.03%	Beta	0.47
Dividend TTM	-	Quick Ratio	1.78	Sales past 5Y	-	Gross Margin	83.34%	52W Low	54.00%	ATR (14)	0.37
Dividend Ex-Date	-	Current Ratio	2.14	EPS Y/Y TTM	53.73%	Oper. Margin	-99.01%	RSI (14)	52.65	Volatility	1.85% 3.19%
Employees	110	Debt/Eq	-	Sales Y/Y TTM	85.03%	Profit Margin	-94.31%	Recom	1.00	Target Price	11.31
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	35.35%	Payout	-	Rel Volume	0.98	Prev Close	5.34
Sales Surprise	1.44%	EPS Surprise	-77.60%	Sales Q/Q	41.97%	Earnings	May 15 BMO	Avg Volume	49.75K	Price	5.39
SMA20	2.49%	SMA50	0.23%	SMA200	9.51%	Trades		Volume	48,594	Change	0.94%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-13-25	Initiated	Lake Street	Buy
Dec-17-24	Initiated	Cantor Fitzgerald	Overweight	$10
Nov-11-24	Initiated	ROTH MKM	Buy	$11
Oct-25-24	Initiated	Northland Capital	Outperform	$12.50
Sep-16-24	Initiated	Oppenheimer	Outperform	$10
May-30-24	Initiated	Canaccord Genuity	Buy	$12

Jun-04-25 08:00AM	TriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System (Business Wire)
May-30-25 07:00AM	TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience (Business Wire) -8.76%
May-16-25 03:01PM	TriSalus Life Sciences Inc (TLSI) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
May-15-25 08:10AM	TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance (Business Wire)
07:15PM	Loading…
May-12-25 07:15PM	OrganiGram (OGI) Reports Q2 Loss, Beats Revenue Estimates (Revised) (Zacks)
04:30PM	TriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference Call (Business Wire)
07:45AM	OrganiGram (OGI) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
May-08-25 06:45PM	TerrAscend Corp. (TSNDF) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
Apr-30-25 08:15AM	SurModics (SRDX) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -10.31%
08:00AM	TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results (Business Wire)
Apr-10-25 11:33AM	VAREX IMAGING (VREX) Moves 16.5% Higher: Will This Strength Last? (Zacks)
Apr-09-25 08:47AM	TriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock? (Zacks)
Mar-30-25 08:02AM	TriSalus Life Sciences: Optimistic Guidance For 2025, But There Are Still Risks (Seeking Alpha)
Mar-27-25 02:02PM	TriSalus Life Sciences, Inc. (TLSI) Q4 2024 Earnings Call Transcript (SeekingAlpha)
08:40AM	Loading…
08:40AM	TriSalus Life Sciences, Inc. (TLSI) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:30AM	TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update (Business Wire)
Mar-26-25 08:00AM	TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav Infusion System Mapping (Business Wire)
Mar-06-25 08:00AM	TriSalus Life Sciences Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of "Intra-arterial Pressure-Enabled Drug Delivery Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model" (Business Wire)
Feb-03-25 04:05PM	TriSalus Life Sciences Announces Key Appointments to Board of Directors (Business Wire)
08:00AM	TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed (Business Wire)
Jan-23-25 08:00AM	TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call (Business Wire) +5.31%
Jan-10-25 08:30AM	TriSalus Life Sciences announces publication of pre-clinical data (TipRanks) +7.95%
Jan-09-25 08:00AM	TriSalus Life Sciences Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres to Liver Tumors using Pressure-Enabled Drug Delivery (PEDD) via the TriNav Infusion System (Business Wire)
Jan-08-25 08:00AM	TriSalus Announces Leadership Changes (Business Wire) -7.18%
Nov-14-24 08:00AM	TriSalus Reports Q3 2024 Financial Results and Provides Business Update (Business Wire) -10.89%
Nov-13-24 07:27AM	TriSalus Life Sciences Inc (TLSI) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Nov-11-24 07:00AM	TriSalus Life Sciences Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav Infusion System to U.S. Veterans with Liver Cancer (Business Wire) +5.91%
Nov-07-24 07:00AM	TriSalus Life Sciences Launches TriNav LV Infusion System and TriGuide Guiding Catheters, Expanding Portfolio of PEDD Devices for Improved Tumor Treatment (Business Wire)
Oct-31-24 08:00AM	TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call (Business Wire)
04:05PM	Loading…
Oct-14-24 04:05PM	TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit (Business Wire)
Sep-26-24 07:00AM	TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board (Business Wire)
Sep-23-24 07:00AM	TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD Method via the TriNav Infusion System (Business Wire) -6.70%
Sep-14-24 01:52AM	TriSalus Life Sciences Inc (TLSI) CEO Buys Shares (GuruFocus.com)
Aug-15-24 08:00AM	TriSalus Reports Q2 2024 Financial Results and Business Update (Business Wire)
Aug-01-24 07:00AM	TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call (Business Wire)
Jul-01-24 04:00PM	TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation (Business Wire) -5.07%
Jun-26-24 05:45PM	TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants (Business Wire)
Jun-03-24 07:00AM	TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting (Business Wire)
May-24-24 06:05AM	TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants (Business Wire) -20.75%
May-15-24 12:53PM	TLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) -7.49%
08:00AM	TriSalus Reports Q1 2024 Financial Results and Business Update (Business Wire)
May-07-24 07:00AM	TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors (Business Wire)
May-06-24 04:58PM	TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call (Business Wire)
Apr-30-24 04:35PM	TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav Infusion System Growth Initiatives (Business Wire)
Apr-01-24 12:53PM	TLSI Stock Earnings: TriSalus Life Sciences Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) +5.13%
09:33AM	TriSalus Life Sciences Inc (TLSI) Q4 and Full Year 2023 Earnings: Revenue Growth Amidst Late ... (GuruFocus.com)
08:00AM	TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update (Business Wire)
Mar-26-24 08:00AM	TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting (Business Wire)
Mar-21-24 08:00AM	TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting (Business Wire)
Mar-11-24 05:15PM	TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results (Business Wire)
Mar-07-24 07:00AM	TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Associations Adopted Name Council for Nelitolimod as the Nonproprietary Drug Name for SD-101 (Business Wire)
Feb-29-24 07:00AM	TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors (Business Wire)
Dec-14-23 07:00AM	TriSalus Life Sciences Announces CMS Reimbursement for the TriNav Infusion System via Assignment of a New Technology Healthcare Common Procedure Coding System (HCPCS) Code (Business Wire) +33.61%
Nov-14-23 12:27PM	TriSalus Life Sciences Inc Reports Revenue Growth and Clinical Advancements in Q3 2023 (GuruFocus.com)
08:00AM	TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Nov-07-23 04:05PM	TriSalus Life Sciences to Host Third Quarter 2023 Financial Results Conference Call (Business Wire) -5.39%
Nov-04-23 02:25PM	Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications (Business Wire)
Nov-03-23 12:00PM	TriSalus Life Sciences Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting (Business Wire) +12.90%
Oct-25-23 09:05AM	TriSalus Life Sciences Announces Late Breaker and Additional Data Presentations on Liver Metastases and Pancreatic Cancer at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting (Business Wire)
Sep-06-23 07:00AM	TriSalus Life Sciences Appoints Jodi Devlin as President of TriSalus Therapeutics (Business Wire) -6.96%
Aug-10-23 04:05PM	TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation (Business Wire) +18.67% +5.82%
Aug-02-23 05:00PM	MedTech Acquisition Corporation Adjourns Special Meeting of Stockholders (Business Wire) -5.60%
Jun-12-23 07:00AM	TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD Method with the TriNav Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual Meeting (Business Wire)
Apr-20-23 07:00AM	TriSalus Life Sciences Presents New Data at AACR for SD-101 Delivered by the Proprietary PEDD Method in Stage IV Uveal Melanoma Patients With Liver Metastases (Business Wire)
Feb-21-23 07:00AM	TriSalus Life Sciences Appoints James Alecxih to Lead Device Technology Business (Business Wire)
Dec-07-22 09:26PM	MedTech Acquisition Corporation Announces Adjournment of its Special Meeting in lieu of an Annual Meeting of Stockholders (GlobeNewswire)
Nov-14-22 04:24PM	Colorado biotech company to go public via SPAC merger (American City Business Journals)
Mar-14-22 02:32PM	Robotic surgery company Memic pulls out of SPAC merger (American City Business Journals)
Mar-10-22 08:11AM	MedTech Acquisition Corporation and Memic Innovative Surgery Ltd. Mutually Agree to Terminate Business Combination (GlobeNewswire)
Jan-06-22 08:00AM	Memic Announces Adoption of Hominis® Surgical System at Three Leading U.S. Hospitals in Q4 2021 (PR Newswire)
Dec-30-21 03:00PM	A look at the South Florida tech companies that were acquired or went public in 2021 (American City Business Journals)
Oct-07-21 09:16AM	Is MedTech Acquisition Corporation (NASDAQ:MTAC) Popular Amongst Institutions? (Simply Wall St.)
Sep-09-21 06:00AM	Memic Announces Robert L. Ryan and Sandra Morgan to Join Board of Directors Upon Closing of Business Combination with MedTech Acquisition Corporation (PR Newswire)
Sep-03-21 09:25AM	Moore Kuehn Encourages FRSG, MTAC, SLCR, and ADF Investors to Contact Law Firm (GlobeNewswire)
Aug-19-21 12:32PM	Peregrine Ventures Portfolio Company Memic Announces $1B Valuation SPAC deal (PR Newswire)
Aug-13-21 05:49PM	SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of MedTech Acquisition Corporation (Nasdaq - MTAC) (ACCESSWIRE)
08:07AM	Memic Innovative Surgery Ltd. and MedTech Acquisition Corporation Announce Proposed Business Combination (PR Newswire)
Jun-02-21 04:05PM	MedTech Acquisition Corporation Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q (GlobeNewswire)
May-19-21 01:02PM	Robotics Firm Memic Is in Talks to Go Public Via SPAC (Bloomberg)

TriSalus Life Sciences, Inc. is an oncology company, which engages in the business of integrating standard-of-care treatments and investigational immunotherapeutic with disruptive pressure enabled drug delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. The company was founded on September 11, 2020, and is headquartered in Westminster, CO.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cox Bryan F.	Chief of Research	May 19 '25	Sale	5.18	4,764	24,678	119,415	May 21 05:33 PM
Devlin Jodi	Chief of Clinical Operations	May 19 '25	Sale	5.18	4,764	24,678	52,764	May 21 05:31 PM
Marshak Richard	Chief Commercial Officer	May 19 '25	Sale	5.18	6,597	34,172	69,101	May 21 05:30 PM
Stevens Jennifer	Chief Regulatory Officer	May 19 '25	Sale	5.18	8,704	45,087	77,640	May 21 05:27 PM
Young James Emmett	Chief Financial Officer	Feb 05 '25	Buy	5.65	6,000	33,900	30,000	Feb 06 06:09 PM
Szela Mary T	CEO AND PRESIDENT	Jan 30 '25	Buy	5.28	5,010	26,453	444,259	Jan 31 05:54 PM
Szela Mary T	CEO AND PRESIDENT	Jan 29 '25	Buy	5.03	5,030	25,301	439,249	Jan 31 05:54 PM
Szela Mary T	CEO AND PRESIDENT	Jan 27 '25	Buy	5.42	4,826	26,157	429,503	Jan 29 06:15 PM
Szela Mary T	CEO AND PRESIDENT	Jan 28 '25	Buy	5.12	4,716	24,146	434,219	Jan 29 06:15 PM
Murphy Sean	Chief Manuf, Strategy&Bus Dev.	Jan 27 '25	Buy	5.31	15,000	79,650	182,732	Jan 29 06:13 PM
Murphy Sean	Chief Manuf, Strategy&Bus Dev.	Jan 28 '25	Buy	5.17	15,000	77,550	197,732	Jan 29 06:13 PM
Young James Emmett	Chief Financial Officer	Jan 27 '25	Buy	5.40	24,000	129,600	24,000	Jan 29 06:03 PM
Cox Bryan F.	CHIEF SCIENTIFIC & MANUFACT.	Oct 05 '24	Sale	4.44	314	1,394	86,382	Dec 19 06:09 PM
Frankenius Equity AB	10% Owner	Dec 17 '24	Buy	3.97	62,972	249,999	6,230,748	Dec 19 06:03 PM
Desai Arjun JJ	Director	Dec 10 '24	Sale	3.69	30,000	110,700	247,127	Dec 12 05:40 PM
Arjun Desai	Board of Directors	Dec 10 '24	Proposed Sale	4.50	30,000	135,000		Dec 10 04:06 PM
Wahlstrom Mats	Director	Nov 22 '24	Buy	4.55	5,000	22,750	15,727	Nov 25 05:53 PM
Wahlstrom Mats	Director	Nov 21 '24	Buy	4.44	8,687	38,570	10,727	Nov 22 07:11 PM
Wahlstrom Mats	Director	Nov 20 '24	Buy	4.16	2,040	8,486	2,040	Nov 22 07:11 PM
Szela Mary T	CEO AND PRESIDENT	Sep 12 '24	Buy	5.20	7,520	39,104	377,382	Sep 13 05:43 PM
Szela Mary T	CEO AND PRESIDENT	Sep 13 '24	Buy	4.97	7,295	36,255	384,677	Sep 13 05:43 PM
Szela Mary T	CEO AND PRESIDENT	Sep 10 '24	Buy	4.97	5,000	24,850	369,862	Sep 12 07:06 PM
Martin George Kelly	Director	Aug 28 '24	Sale	5.50	9	50	247,176	Sep 10 05:42 PM

CHRS

Coherus Oncology Inc

TLSI

TriSalus Life Sciences Inc

Upgrade your FINVIZ experience